NASDAQ · VECT
VectivBio Holding AG
$16.87+$0.02 (+0.12%)
VectivBio Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.65% below the high.
Loading market information…
NASDAQ · PSTX · USD
Stock price, earnings
Quote as of Jan 7, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Poseida Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.76% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Poseida Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:49 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $20.01M+294.73% vs estimate |
| Q1 2023 | May 9, 2023 | -$0.45-12.5% vs estimate | $10.34M+10.38% vs estimate |
|---|
| Q4 2022 | Mar 9, 2023 | -$0.39-182.98% vs estimate | $9.92M-83.92% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$16.87+$0.02 (+0.12%)
VectivBio Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.65% below the high.
$11.13+$0.03 (+0.27%)
Verve Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.41% below the high.
$44.15$0.00 (0.0%)
Albireo Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.39% below the high.
$23.01+$0.02 (+0.09%)
Harpoon Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
$8.54$0.00 (0.0%)
Chimerix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
$12.49$0.00 (0.0%)
Avid Bioservices, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.16% below the high.
$19.00+$0.04 (+0.21%)
Intercept Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.08% below the high.
$15.31-$0.14 (-0.91%)
Icosavax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.94% below the high.
